Cytokinetics, Incorporated (NASDAQ: CYTK) Faces Securities Fraud Lawsuit Amid Executive Stock Sale

Cytokinetics is involved in a securities fraud class action lawsuit due to alleged misleading statements about drug development timelines.Executive Vice President of Research & Development at Cytokinetics sold 2,105 shares amid the ongoing lawsuit.The company's financials show a negative P/E ratio of -11.38, a high price-to-sales ratio of 80.64, and a current ratio of 6.76, indicating mixed financial health.Cytokinetics, Incorporated (NASDAQ: CYTK) is a biopharmaceutical company focused on developing muscle ...